Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab

OBJECTIVES: COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers mu...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Transl Immunology
Huvudupphovsmän: Caballero, Armando, Filgueira, Lázaro M, Betancourt, Julio, Sánchez, Naivy, Hidalgo, Carlos, Ramírez, Alberto, Martinez, Alejandro, Despaigne, Rolando E, Escalona, Alberto, Diaz, Henrry, Meriño, Elio, Ortega, Lilia M, Castillo, Ulises, Ramos, Mayra, Saavedra, Danay, García, Yanelda, Lorenzo, Geydi, Cepeda, Meylán, Arencibia, Maylén, Cabrera, Leticia, Domecq, Milagros, Estévez, Daymys, Valenzuela, Carmen, Lorenzo, Patricia, Sánchez, Lizet, Mazorra, Zaima, León, Kalet, Crombet, Tania
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2020
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7688906/
https://ncbi.nlm.nih.gov/pubmed/33304584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1218
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk